- New patient preference survey
confirms that patients value clear skin the most, but expect
additional benefits from their treatment, such as proven long-term
efficacy and safety data and no injection site
reactions[1]
- A separate
ranking incorporating additional characteristics showed
that effectiveness in treating multiple manifestations of psoriatic
disease was also important[1]
- The number of injections per
dose and injection frequency were least important to patients
according to the ranking analysis[1]
Basel, September 12, 2018
- Novartis, a leader in
immuno-dermatology, announced today new data from a patient
preference survey showing psoriasis patients want their treatment
to go beyond just clear skin and safety. This study of 300
psoriasis patients is being presented during a poster session at
the 27th European
Academy of Dermatology and Venereology (EADV) Congress in Paris,
France.
Results confirmed that clear skin
is the most preferred treatment attribute, which is consistent with
previous patient preference surveys in psoriasis[2]-[5]. Results
also show patients expect additional benefits from their treatment
that are not traditionally assessed in patient surveys, including
the number of years of proven efficacy and safety data in large
clinical trials and no injection site reactions[1].
In a separate ranking incorporating additional
characteristics, patients ranked the effectiveness in treating
multiple manifestations of psoriatic disease (including PsA, nail,
palmoplantar and scalp), and complete symptom relief, as being
important, after risk of side effects and clear skin (including
time to achieve clear skin)[1]. Least important were the number of
injections per dose and injection frequency[1].
"It's relevant to understand from
psoriasis patients which additional benefits from their treatment
they want besides clear skin and safety," said Professor
Matthias Augustin, Director Institute of Health Care Research
in Dermatology and Nursing, University of Hamburg. "From the
findings of this survey, consistent and sustained long term
efficacy and safety from large clinical studies, no pain at
injection site or efficacy in all manifestations of psoriatic
disease could be influential when choosing a treatment for
moderate-to-severe psoriasis."
"The survey will help Novartis and dermatologists
better understand patient preference in selecting psoriatic disease
treatment options," stated Sam Khalil, PhD, Head Worldwide Medical
Affairs, Immunology, Hepatology and Dermatology. "It supports
Novartis goal of leadership in immuno-dermatology and our
commitment to improving patient care. Reimagining medicine for
patients, starts by listening to what patients truly want and
need."
Psoriatic disease is complex and multifaceted. Up
to 40% of psoriasis patients may develop PsA[6]. In the long term,
up to 90% of psoriasis patients may also develop nail psoriasis,
palmoplantar psoriasis (of the palms of the hands and soles of the
feet), or scalp psoriasis[8]-[10]. These manifestations are
associated with a greater burden on patients' life.
According to the American Academy of Dermatology's
guidelines, psoriasis treatments should be tailored to the
patient's situation and preference[11]. A greater understanding of
patients' preferences for moderate-to-severe psoriasis treatment is
central to improving models of shared patient-doctor decision
making. These results provide additional insight into the patients'
perspective of the psoriasis treatment options available.
About the patient preference
study[1]
The aim of the patient preference study was to quantify the
relative patient preferences for five selected attributes that may
differentiate among biologic treatments for moderate-to-severe
plaque psoriasis. The data was collated from an online discrete
choice experiment (DCE) survey from 300 US respondents with a
self-reported physician diagnosis of moderate-to-severe psoriasis.
Levels of attributes were based on existing clinical information
for current biologic treatments of moderate-to-severe plaque
psoriasis.
In addition, patients ranked the importance of an
expanded list of treatment attributes, which included the five DCE
attributes plus five additional psoriasis-relevant treatment
attributes, in a separate and exploratory series of direct
questions.
About psoriasis
Psoriasis is a distressing and painful autoimmune disease that
affects more than 125 million people worldwide[7]. It is a
debilitating condition associated with a significant emotional and
physical daily burden. In the long-term, psoriasis can also lead to
other conditions, such as diabetes, heart disease, depression and
psoriatic arthritis (PsA) - which up to 40% of patients with
psoriasis may develop[6].
Plaque psoriasis is the most common form of the
disease and appears as raised, red skin patches covered with a
silvery white build-up of dead cells. Most patients with psoriasis
will also develop difficult-to-treat forms of the disease which
appear on the scalp, nails, palms of the hands or soles of the feet
and are associated with further pain, decreased mobility and
functional impairment[8]-[10],[12].
About Novartis Immunology &
Dermatology
Novartis is a global leader in Immunology & Dermatology. We are
dedicated to transforming the lives of people living with
immunologic diseases, focusing on immunodermatology, rheumatology
and specialty liver diseases. Our Immunology & Dermatology
pipeline includes multiple compounds in liver disease and other
immunological areas where high unmet medical needs exist.
Disclaimer
This press release contains forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. Forward-looking statements can generally be identified
by words such as "potential," "can," "will," "plan," "expect,"
"anticipate," "look forward," "believe," "committed,"
"investigational," "pipeline," "launch," or similar terms, or by
express or implied discussions regarding potential marketing
approvals, new indications or labeling for the investigational or
approved products described in this press release, or regarding
potential future revenues from such products. You should not place
undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that the
investigational or approved products described in this press
release will be submitted or approved for sale or for any
additional indications or labeling in any market, or at any
particular time. Nor can there be any guarantee that such products
will be commercially successful in the future. In particular, our
expectations regarding such products could be affected by, among
other things, the uncertainties inherent in research and
development, including clinical trial results and additional
analysis of existing clinical data; regulatory actions or delays or
government regulation generally; global trends toward health care
cost containment, including government, payor and general public
pricing and reimbursement pressures; our ability to obtain or
maintain proprietary intellectual property protection; the
particular prescribing preferences of physicians and patients;
general political and economic conditions; safety, quality or
manufacturing issues; potential or actual data security and data
privacy breaches, or disruptions of our information technology
systems, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press
release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the
evolving needs of patients and societies. Headquartered in Basel,
Switzerland, Novartis offers a diversified portfolio to best meet
these needs: innovative medicines, cost-saving generic and
biosimilar pharmaceuticals and eye care. Novartis has leading
positions globally in each of these areas. In 2017, the Group
achieved net sales of USD 49.1 billion, while R&D throughout
the Group amounted to approximately USD 9.0 billion. Novartis Group
companies employ approximately 125,000 full-time-equivalent
associates. Novartis products are sold in approximately 155
countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow
@Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit
www.novartis.com/news/media-library
For questions about the site or required registration, please
contact media.relations@novartis.com
References
[1] Feldman S, et al. Exploring Patient
Preferences for the Treatment of Moderate to Severe Psoriasis: a
Discrete Choice Experiment Study in the US, Abstract presented at
EADV, 2018
[2] Niedhardt K. Patient-Relevant Endpoints In
Psoriasis - A Literature Review Of Patient Preference Studies.
Value Health. 2016;19(7):a571
[3] Kauf T L , et al. Psoriasis patients'
willingness to accept side-effect risks for improved treatment
efficacy. Journal of Dermatological Treatment.
2015;26(6):507-513
[4] Feldman S, et al. Journal of Health Economics
and Outcomes Research. 2016;4(2):141-15
[5] Gonzalez J M, et al. Comparing preferences
for outcomes of psoriasis treatments among patients and
dermatologists in the UK: results from a discrete-choice
experiment. British Journal of Dermatology. 2017;176(3)
777-785
[6] Mease P J, et al. Managing patients with
psoriatic disease: the diagnosis and pharmacologic treatment of
psoriatic arthritis in patients with psoriasis. Drugs
2014;74:423-41.
[7] International Federation of Psoriasis
Associations (IFPA) World Psoriasis Day website. "About Psoriasis."
Available at:
http://www.worldpsoriasisday.com/web/page.aspx?refid=114. Last
accessed January 2018.
[8] Baran R. The burden of nail psoriasis: an
introduction. Dermatol. 2010:221 Suppl 1:1-5.
[9] Kumar B, et al. Palmoplantar lesions in
psoriasis: a study of 3065 patients. Acta Dermatol Venereol.
2002;82:192-5.
[10] Zampieron A, et al. Quality of life in patients with
scalp psoriasis. G Ital Dermatol Venereol. 2015
Jun;150(3):309-16
[11] Menter, et al. Journal of the American Academy of
Dermatology. 2008; 58(5):826-50
[12] Chung J, et al. Palmoplantar psoriasis is associated
with greater impairment of health-related quality of life compared
with moderate to severe plaque psoriasis. J Am Acad Dermatol.
2014;71(4):623-32.
# # #
Novartis Media
Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Eric
Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com |
Friedrich
von Heyl
Novartis Global Pharma Communications
+41 61 324 8984 (direct)
+41 79 749 0286 (mobile)
friedrich.vonheyl@novartis.com |
Novartis Investor
Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central |
|
North
America |
|
Samir
Shah |
+41 61
324 7944 |
Richard
Pulik |
+1 212
830 2448 |
Pierre-Michel Bringer |
+41 61
324 1065 |
Cory
Twining |
+1 212
830 2417 |
Thomas
Hungerbuehler |
+41 61
324 8425 |
|
|
Isabella
Zinck |
+41 61
324 7188 |
|
|
Media release (PDF)